Single Photon Emission Computed Tomography (SPECT) Market

Single Photon Emission Computed Tomography (SPECT) Market Outlook (2022-2026)

Expanding at a CAGR of 6.8%, the global single photon emission computed tomography (SPECT) market is projected to increase from a valuation of US$ 2 billion in 2022 to US$ 2.6 billion by the end of 2026.

The cardiology application segment is anticipated to increase at a significant rate during the forecast period (2022-2026). Increasing prevalence of cardiovascular disorders, rising adoption of cardiovascular OCT imaging techniques, and growing public awareness about heart disease diagnosis are reasons for rapid segmental growth.

Report Attributes	Details
Single Photon Emission Computed Tomography Market Size (2022)	US$ 2 Billion
Projected Market Value (2026)	US$ 2.6 Billion
Global Market Growth Rate (2022-2026)	6.8% CAGR
Market Share of Standalone Systems	55%
Key Companies Profiled	Bracco Imaging Siemens Healthcare Novartis AG Mediso Ltd. Bruker Corporation Cadinal Health Inc. Curium DDD-Diagnostic A/S Digirad Corporation GE Healthcare (GE Company) Koninklijke Philips N.V. MiE America, Inc. Spectrum Dynamics Medical Beijing Hamamatsu Photon Techniques Inc.

Revenue Analysis of Single Photon Emission Computed Tomography (2017-2021) Vs. Market Outlook (2022-2026)

“Increasing Investments in Advanced SPECT Scanning Services”

According to Fact.MR, a market research and competitive intelligence provider, demand for single photon emission computed tomography systems is expected to increase at a CAGR of 6.8% from 2022 to 2026.

A nuclear imaging scan uses a radioactive tracer and computed tomography (CT) to produce a diagnostic. By producing gamma rays that the CT scanner can detect, the radiolabeled tracer enables medical personnel to evaluate how blood passes to organs and tissues.

Gamma ray emissions are used to generate data, which is subsequently shown on CT cross-sections by computers. These cross-sections are used to represent the brain and other organs in three dimensions.

Using cardiac single photon emission computed tomography scans, the blood flow through the heart is assessed; areas of the heart with insufficient blood flow will appear dark, whereas areas with normal blood flow would seem light.

Additionally, it is employed in the diagnosis of concealed bone fractures, including stress fractures and shin splints. The single emission computed tomography market is expanding due to rising investments in advanced SPECT scanning services and growing public awareness about disease diagnosis.

Which Key Market Factors are Driving Demand for Single Photon Emission Computed Tomography Systems?

“Rising Need for Accurate System Calibration & Operation for Better-quality Outcomes Driving Market Value”

A single photon emission computed tomography scan can identify blood flow through arteries and veins in the brain and spine. Single photon emission computed tomography systems may provide better accurate results for brain injury because they are used to identify decreased blood flow to injured regions.

Recent advancements in medical imaging have made the combination of X-ray computed tomography (CT) and single photon emission computed tomography a vital diagnostic tool where anatomical details can distinguish between functional and metabolic data.

Single photon emission computed tomography systems can be useful in the identification of attacks, tremors, and Alzheimer's disease, among other conditions. Both 2D and 3D images are produced using single photon emission computed tomography scanners. Rising need for accurate system calibration and operation for better-quality outcomes driving the demand for tomographic imaging techniques.

The market is expanding as a result of advancements in single photon emission computed tomography technology as well as rising incidence of cardiovascular and cancer disorders across the world.

What are the Challenging Factors for Market Expansion?

“Lack of Funding for Advanced Medical Facilities & Side Effects of Radiopharmaceuticals”

Market expansion is anticipated to be hampered by the radioisotopes' shorter half-lives, the lack of essential healthcare services, the high price of reagents, side effects of radiopharmaceuticals, and susceptibility to storage conditions.

While molecular isotopes are necessary for diagnostic imaging services, their scarcity and inadequate supply are projected to limit the growth of the worldwide single photon emission computed tomography market throughout the projection period.

Another element that is having a detrimental effect on the global market for SPECT is product recalls. Adverse consequences are linked to the use of single photon emission tomography devices in the diagnosis, staging, restaging, and follow-up of lesions, illnesses, and organ dysfunctions, including cancer, cardiovascular disease, and brain dysfunction.

The emission computed tomography market is experiencing difficulties in terms of revenue growth due to product recalls because of the negative consequences of single photon emission computed tomography devices.

Poor health care systems and lack of funding for advanced medical facilities are also anticipated to impede expansion of the market over the forecast period.

How are Start-ups Contributing to Market Expansion?

“New Market Entrants Focused on Development of 3D Imaging Methods for Better Diagnosis”

Image screening frequently makes it feasible to find cancer early on. However, because cancer cells are surrounded by other cells, two-dimensional images do not fully capture the situation.

Consequently, 3D imaging of cancer cells is becoming a tool for better diagnosis. New companies are developing such methods to record even the smallest details of tumors.

• Survon, a start-up based in the U.S., can examine individual live cancer cells in three dimensions using micro-computed tomography (micro-CT) technology. The business employs computer vision to extract information and changes at the microscopic level from 3D photos of cancer cells. The technology uses machine learning to produce a personalized digital representation of the tumor, enabling doctors to track, evaluate, and forecast.

Which Region Dominates the SPECT Market?

“Increase in Awareness Campaigns for Cancer and Cardiovascular Illnesses in North America”

North America holds the highest share in the single photon emission computed tomography market. The huge ageing population, high prevalence of cancer cases, and a high number of cardiac patients are all driving market growth in the region.

The market in North America is driven by the growing usage of emission computerized tomography systems for the early detection and treatment of disease.

The presence of prominent players, favorable regulations on radiopharmaceutical products, supportive government policies related to health care infrastructure, and a rise in awareness campaigns for cancer and cardiovascular illnesses are the primary drivers boosting market expansion in the region.

Country-wise Insights

How Will the SPECT Market Perform in the U.S.?

“Recent Advances in Molecular Imaging Driving Market Growth in the U.S.”

Advances in molecular imaging, the emergence of new radiopharmaceuticals for diagnostics, and other technological breakthroughs are driving the growth of the single photon emission computed tomography market in the United States.

Rapid expansion of the healthcare industry, the rising prevalence of coronary artery disorders, rising adoption of dual-modality and organ-specific systems are driving the market growth.

Why is the China SPECT Market Expected to Be Highly Lucrative?

“Introduction of Novel Radionuclides for Diagnostics to Drive Market Growth in China”

The single photon emission computed tomography market in China is projected to increase at a CAGR of 9% from 2022 to 2026.

The China SPECT market is anticipated to expand quickly due to the growing population, changing lifestyles, increased patient awareness, and rising per capita spending. The expansion of pharmaceutical distribution channels and improvements in health care infrastructure are the factors projected to fuel market expansion in China.

The market in China is expanding due to technological advancements such as multimodal imaging, introduction of novel radionuclides for diagnostics, and rising demand for better imaging devices.

Category-wise Insights

Which SPECT Product is Expected to Hold a Dominant Market Share?

“Standalone Systems Widely Preferred for Precise Illness Staging and Early Disease Diagnosis”

Based on product, the single photon emission computed tomography market is classified into standalone and hybrid. Standalone systems account for 55% share of the global market. Standalone systems are most frequently used, particularly in oncology and cardiology applications.

The device can create high full-body tomographic images in real-time and identifies the gamma-ray emissions from an injected radioisotope to generate images for diagnosis and illness management.

Additional benefits of standalone systems include precise illness staging and early diagnosis. In recent years, technological innovations for standalone systems have increased as well.

Which Radioisotope Accounts for Highest Revenue Generation?

“Growing Usage of Ga-67 Radioisotope for Imaging of Inflammation”

On the basis of radioisotope, the market is segmented into Tc-99m, Ra-223, Ga-67, I-123, and others.

Inflammation and infections such as Hodgkin's disease, lymphomas other than lymphocytic ones, hepatomas, and bronchogenic carcinoma are all diagnosed with the gallium-67 radioisotope. It serves primarily as a bone imaging agent.

Ga-67 radioisotope offers accurate localization of lymphoma lesions. Ga-67 is a frequently utilized agent for the imaging of inflammation. Rising incidence of cancer, driving the demand for Ga-67 radioisotopes for disease diagnosis and treatment.

Competitive Landscape

Key market players can supply items that are both safe and efficient since they have sufficient resources and technical expertise. Most of the major vendors have been observed investing a significant percentage of their funding in product R&D.

Additionally, they are concentrating on organic development initiatives, such as product launches, to significantly differentiate their offerings and increase client penetration. By employing price-cutting techniques and expanding their local clientele, small-scale suppliers are competing with established market players.

For instance :

• In 2022, with two pipeline radiopharmaceuticals - one for Positron Emission Tomography (PET) and the other for single-photon release calculated tomography imaging - GE Healthcare intends to expand its product line. Recently, the company announced that the first patient had been given medication in a Phase III clinical trial for a PET radiopharmaceutical imaging intermediary that aims to help with the evaluation of adult patients with alleged Parkinsonian syndromes, provide research, and enhance patient maintenance.

Single Photon Emission Computed Tomography Industry Research Segmentation

• By Product :

  • Standalone
  • Hybrid

• By Radioisotope :

  • Tc-99m
  • Ra-223
  • Ga-67
  • I-123
  • Others

• By Application :

  • Cardiology
  • Oncology
  • Neurology
  • Others

• By End User :

  • Hospitals
  • Diagnostic Centers
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa